Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close. Aurinia’s management team will host a conference call to discuss the Company’s financial results and to provide a general business update.

The conference call and webcast is scheduled for February 24, 2021 at 4:30pm ET. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

Investor Contact: Glenn Schulman, PharmD, MPH SVP, Corporate Communications & IR gschulman@auriniapharma.com

Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Aurinia Pharmaceuticals Charts.
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Aurinia Pharmaceuticals Charts.